Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AWAWU E IGBINADOLOR

Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine

NPI
1386658128
CMS profile
334690
Location
MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,264.02

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,528.15 7
Food and Beverage $735.87 7

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Alnylam Pharmaceuticals Inc. $2,070.10 7
Novartis Pharmaceuticals Corporation $1,054.59 5
Amgen Inc. $125.00 1
AstraZeneca Pharmaceuticals LP $14.33 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AWAWU E IGBINADOLOR

NPI 1386658128 · CMS profile ID 334690

Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine

MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $3,264.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $235.6909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785835 CMS
Novartis Pharmaceuticals Corporation $526.1309/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785837 CMS
Novartis Pharmaceuticals Corporation $9.0909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785839 CMS
Novartis Pharmaceuticals Corporation $111.1509/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785843 CMS
Novartis Pharmaceuticals Corporation $172.5309/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785841 CMS
Alnylam Pharmaceuticals Inc. $371.7404/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853427 CMS
Alnylam Pharmaceuticals Inc. $151.9704/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853431 CMS
Alnylam Pharmaceuticals Inc. $82.8604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853433 CMS
Alnylam Pharmaceuticals Inc. $105.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853435 CMS
Alnylam Pharmaceuticals Inc. $125.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853437 CMS
Alnylam Pharmaceuticals Inc. $1,081.5604/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853425 CMS
Alnylam Pharmaceuticals Inc. $151.9704/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853429 CMS
AstraZeneca Pharmaceuticals LP $14.3301/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104408293 CMS
Amgen Inc. $125.0001/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111604726 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.59 19
PY2020 $250.77 11
PY2021 $613.59 23
PY2022 $635.48 38
PY2023 $1,376.29 8
PY2024 $3,264.02 14
PY2025 $15.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,807,545.77 332
PY2024 Recipient $24,803.18 2
PY2024 Principal investigator $5,575,092.65 467
PY2023 Recipient $5,441.70 12
PY2023 Principal investigator $4,002,304.15 759
PY2022 Recipient $99,385.00 2
PY2022 Principal investigator $3,185,482.26 500
PY2021 Recipient $421,014.16 3
PY2021 Principal investigator $3,556,229.85 34
PY2020 Recipient $145,488.66 2
PY2019 Principal investigator $9,471.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

771 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $456.49 12/31/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991125429
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042523729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137815
Principal investigator 1 PFIZER INC. $844.56 12/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046258947
Principal investigator 1 PFIZER INC. $10,950.00 12/22/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046172903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 12/20/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 12/20/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 12/20/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127831
Principal investigator 1 ModernaTX, Inc. $93,260.81 12/20/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1041747817
Principal investigator 1 ModernaTX, Inc. $3,427.50 12/20/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747829
Principal investigator 1 ModernaTX, Inc. $229.50 12/20/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747835
Principal investigator 1 PFIZER INC. $18.80 12/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046068783
Principal investigator 1 CIPLA USA INC. $800.00 12/14/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1060145191
Principal investigator 1 ModernaTX, Inc. $9,493.75 12/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127595
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $742.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 12/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137124
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137203
Principal investigator 1 ModernaTX, Inc. $201,803.48 11/29/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1041747805
Principal investigator 1 PFIZER INC. $403.92 11/22/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045996713
Principal investigator 1 Eli Lilly and Company $100,000.00 11/14/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1038114053
Principal investigator 1 Eli Lilly and Company $30,170.00 11/13/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1038138353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,955.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,955.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,101.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,353.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 11/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137063
Principal investigator 1 Eli Lilly and Company $10,688.00 10/30/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1038113967
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746715
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746721
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746727
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746733
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746739
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746745
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746751
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746757
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746763
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746769
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746775
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746779
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746785
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746791
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746797
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746803
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746809
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746815
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746821
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746827
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746833
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746839
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746845
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746851
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746857
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746863
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746867
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746875
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746881
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746885
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746893
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746899
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746905
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746909
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746915
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746921
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746927
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746933
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746939
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746945
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746951
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747491
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747497
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747503
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747509
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747515
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747521
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747527
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747535
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747541
Principal investigator 1 ModernaTX, Inc. $4,411.67 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747547
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747553
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747559
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747563
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747569
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747575
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747581
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747587
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747593
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747599
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747605
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747611
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747617
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747623
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747629
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747635
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747641
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747647
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747653
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747659
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747665
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747671
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747677
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747683
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747689
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747695
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747701
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747707
Principal investigator 1 ModernaTX, Inc. $2,731.93 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747715
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747721
Principal investigator 1 ModernaTX, Inc. $742.37 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747727
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747733
Principal investigator 1 ModernaTX, Inc. $1,869.89 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747739
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747745
Principal investigator 1 ModernaTX, Inc. $651.24 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747751
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747757
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747763
Principal investigator 1 ModernaTX, Inc. $7,900.00 10/25/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747781
Principal investigator 1 AstraZeneca UK Limited $83,077.00 10/20/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 991135385
Principal investigator 1 SANOFI US SERVICES INC. $1,659.38 10/18/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973778
Principal investigator 1 ModernaTX, Inc. $17,236.25 10/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747775
Recipient SANOFI PASTEUR INC. $55.00 10/06/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888893
Recipient SANOFI PASTEUR INC. $30.00 10/06/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888905
Recipient SANOFI PASTEUR INC. $72.00 10/06/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888917
Recipient SANOFI PASTEUR INC. $536.62 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888819
Recipient SANOFI PASTEUR INC. $269.00 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888831
Recipient SANOFI PASTEUR INC. $52.45 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888843
Recipient SANOFI PASTEUR INC. $68.00 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888855
Recipient SANOFI PASTEUR INC. $30.00 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888867
Recipient SANOFI PASTEUR INC. $136.00 10/05/2023 Covered Recipient Physician A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) No dispute reported 06/30/2026 1035888877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165,536.00 10/02/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $87,972.30 09/25/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997127415
Principal investigator 1 Eli Lilly and Company $249.59 09/21/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1038118889
Principal investigator 1 ModernaTX, Inc. $7,387.50 09/13/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747485
Principal investigator 1 PFIZER INC. $403.92 09/05/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045944327
Principal investigator 1 Janssen Pharmaceuticals, Inc $10,239.00 09/01/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136704
Principal investigator 1 PFIZER INC. $2,799.90 08/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045995671
Principal investigator 1 PFIZER INC. $816.48 08/17/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046148403
Principal investigator 1 Eli Lilly and Company $2,769.66 08/15/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1038118879
Principal investigator 1 PFIZER INC. $456.30 08/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046252667
Principal investigator 1 PFIZER INC. $1,224.72 08/09/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046250232
Principal investigator 1 PFIZER INC. $2,000.00 08/08/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046221171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54,182.70 08/04/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136537
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/28/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747473
Principal investigator 1 ModernaTX, Inc. $10,867.50 07/28/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747479
Principal investigator 1 PFIZER INC. $11,912.00 07/27/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045996959
Principal investigator 1 PFIZER INC. $868.02 07/25/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045946941
Principal investigator 1 SANOFI US SERVICES INC. $1,042.47 07/24/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973769
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,561.00 07/21/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $69,588.00 07/19/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137435
Principal investigator 1 PFIZER INC. $2,604.06 07/18/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046337804
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18,990.00 07/17/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137429
Principal investigator 1 PFIZER INC. $26,680.68 07/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046054223
Principal investigator 1 Eli Lilly and Company $4,283.03 07/11/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038119983
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,876.94 07/11/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) No dispute reported 06/30/2026 1017214413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 07/09/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136371
Principal investigator 1 PFIZER INC. $408.24 07/06/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046200229
Principal investigator 1 ModernaTX, Inc. $4,910.00 07/05/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747467
Principal investigator 1 PFIZER INC. $186.88 07/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 1046049233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136165
Principal investigator 1 PFIZER INC. $2,449.44 06/29/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046328791
Recipient Eli Lilly and Company $223.39 06/27/2023 Covered Recipient Physician A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1038047765
Recipient Eli Lilly and Company $201.49 06/27/2023 Covered Recipient Physician PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1038058807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $240,862.50 06/26/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137341
Principal investigator 1 PFIZER INC. $816.48 06/22/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046312355
Principal investigator 1 PFIZER INC. $691.20 06/21/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 1046076254
Principal investigator 1 PFIZER INC. $2,449.44 06/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046339783
Principal investigator 1 PFIZER INC. $7,334.01 06/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046021537
Principal investigator 1 PFIZER INC. $5,307.12 06/14/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045985391
Principal investigator 1 PFIZER INC. $4,813.20 06/13/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046022381
Principal investigator 1 PFIZER INC. $121.50 06/06/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046141229
Principal investigator 1 Eli Lilly and Company $789.28 06/05/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1038119993
Principal investigator 1 PFIZER INC. $13,063.68 06/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046063465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,904.00 06/02/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137335
Principal investigator 1 Chiesi USA, Inc. $5,547.00 06/01/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136292
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997136341
Principal investigator 1 PFIZER INC. $228.15 05/30/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045942265
Principal investigator 1 PFIZER INC. $1,224.72 05/25/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046201459
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,787.00 05/24/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094965
Principal investigator 1 ModernaTX, Inc. $9,534.25 05/24/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747461
Principal investigator 1 PFIZER INC. $587.00 05/24/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045891655
Principal investigator 1 PFIZER INC. $456.30 05/23/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046311574
Principal investigator 1 PFIZER INC. $408.24 05/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045976867
Principal investigator 1 SANOFI US SERVICES INC. $2,594.87 05/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973759
Principal investigator 1 Janssen Pharmaceuticals, Inc $29,500.00 05/12/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094963
Principal investigator 1 PFIZER INC. $6,000.00 05/11/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046153733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $117,730.80 05/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137327
Principal investigator 1 PFIZER INC. $4,090.50 05/02/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046059505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135486
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135999
Principal investigator 1 PFIZER INC. $4,090.50 04/25/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046302871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,240.00 04/24/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137321
Principal investigator 1 ModernaTX, Inc. $66.60 04/24/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041746709
Principal investigator 1 Janssen Pharmaceuticals, Inc $13,244.00 04/19/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094971
Principal investigator 1 PFIZER INC. $1,363.50 04/18/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045996741
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,100.00 04/17/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094969
Principal investigator 1 SANOFI US SERVICES INC. $3,258.28 04/17/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973747
Principal investigator 1 PFIZER INC. $20,418.00 04/14/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046163965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $273,624.00 04/12/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137315
Principal investigator 1 PFIZER INC. $8,078.40 04/11/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046302289
Principal investigator 1 Janssen Pharmaceuticals, Inc $17,952.00 04/07/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094967
Principal investigator 1 PFIZER INC. $1,786.05 04/05/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045967827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30,143.70 03/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137259
Principal investigator 1 PFIZER INC. $70,153.20 03/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046042579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $84.00 03/26/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134841
Principal investigator 1 ModernaTX, Inc. $5,000.00 03/24/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747451
Principal investigator 1 ModernaTX, Inc. $1,200.00 03/24/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041747457
Principal investigator 1 PFIZER INC. $8,640.00 03/24/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1045937595
Principal investigator 1 Janssen Pharmaceuticals, Inc $25,811.00 03/22/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094961
Principal investigator 1 PFIZER INC. $31,872.00 03/22/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1045968689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $77,949.00 03/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137253
Principal investigator 1 SANOFI US SERVICES INC. $1,341.34 03/13/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973737
Principal investigator 1 Janssen Pharmaceuticals, Inc $13,600.00 03/08/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094957
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,882.57 03/08/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) No dispute reported 06/30/2026 1017213967
Principal investigator 1 Mylan Specialty L.P. $306.43 03/07/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038209329
Principal investigator 1 PFIZER INC. $44,359.68 03/04/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046139229
Principal investigator 1 PFIZER INC. $8,500.00 03/04/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046291451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135381
Principal investigator 1 PFIZER INC. $11,134.50 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 1046153105
Principal investigator 1 PFIZER INC. $27,964.44 02/28/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046210807
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,980.00 02/23/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094955
Principal investigator 1 PFIZER INC. $5,246.00 02/22/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046295613
Principal investigator 1 PFIZER INC. $3,459.78 02/18/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045893943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $660.00 02/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $880.00 02/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $660.00 02/16/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134965
Principal investigator 1 PFIZER INC. $2,188.80 02/15/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045933219
Principal investigator 1 PFIZER INC. $351.00 02/14/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045958755
Principal investigator 1 PFIZER INC. $14,004.00 02/11/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046128545
Principal investigator 1 PFIZER INC. $5,040.00 02/11/2023 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1046280011
Principal investigator 1 PFIZER INC. $1,729.89 02/10/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046040937
Principal investigator 1 Mylan Specialty L.P. $1,437.70 02/09/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038209335
Principal investigator 1 PFIZER INC. $6,919.56 02/07/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046091199
Principal investigator 1 PFIZER INC. $2,289.60 02/07/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046287387
Principal investigator 1 CIPLA USA INC. $4,775.58 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139351
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139357
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139363
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139369
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139375
Principal investigator 1 CIPLA USA INC. $279.29 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060139381
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140675
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140679
Principal investigator 1 CIPLA USA INC. $2,529.17 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140685
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140691
Principal investigator 1 CIPLA USA INC. $279.29 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140735
Principal investigator 1 CIPLA USA INC. $4,775.58 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140741
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140747
Principal investigator 1 CIPLA USA INC. $1,976.93 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140753
Principal investigator 1 CIPLA USA INC. $1,976.93 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140759
Principal investigator 1 CIPLA USA INC. $1,555.74 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140765
Principal investigator 1 CIPLA USA INC. $2,218.16 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140807
Principal investigator 1 CIPLA USA INC. $4,775.58 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140813
Principal investigator 1 CIPLA USA INC. $1,555.74 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140819
Principal investigator 1 CIPLA USA INC. $2,529.17 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140827
Principal investigator 1 CIPLA USA INC. $279.29 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140833
Principal investigator 1 CIPLA USA INC. $2,529.17 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140839
Principal investigator 1 CIPLA USA INC. $440.02 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140845
Principal investigator 1 CIPLA USA INC. $2,218.16 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140851
Principal investigator 1 CIPLA USA INC. $1,976.93 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140857
Principal investigator 1 CIPLA USA INC. $1,555.74 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140865
Principal investigator 1 CIPLA USA INC. $2,218.16 02/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
Not supplied No dispute reported 06/30/2026 1060140873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,000.00 02/03/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997137235
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,547.14 02/03/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 991125121
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,404.69 02/03/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991125997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $25,365.60 02/01/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134238
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997134511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997135241
Principal investigator 1 Eli Lilly and Company $23,425.19 01/31/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038122811
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,225.00 01/25/2023 Non-covered Recipient Entity
Monroe Biomdcl Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094959
Principal investigator 1 PFIZER INC. $5,942.70 01/24/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046353111
Principal investigator 1 SANOFI US SERVICES INC. $6,156.60 01/23/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1035973727
Principal investigator 1 PFIZER INC. $2,150.55 01/17/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045945735
Principal investigator 1 PFIZER INC. $189.80 01/14/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046343209
Principal investigator 1 PFIZER INC. $9,215.91 01/11/2023 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045968043
Recipient Eli Lilly and Company $3,767.75 01/10/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038048123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $97,656.30 01/06/2023 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137241
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,800.00 01/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 1035815589
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 01/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 1035815601
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,199.90 01/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 1035815613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 01/06/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 1035815627
Principal investigator 1 Eli Lilly and Company $627,386.00 01/03/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038112009
Principal investigator 1 Eli Lilly and Company $460,438.05 01/03/2023 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038122801